文献速递肿瘤 PET/CT放射性药物与辐射防护

高特异性放射性核素标记非阻断纳米抗体的剂量递增生物分布、正电子发射断层显像/计算机断层显像及剂量学研究

Dose escalation biodistribution, positron emission tomography/computed tomography imaging and dosimetry of a highly specific radionuclide-labeled non-blocking nanobody.
PubMed 文献 · EJNMMI Res · 2021-10-30

本研究通过放射性核素68Ga经NOTA螯合剂标记Nb109制备68Ga-NOTA-Nb109,在荷A375-hPD-L1肿瘤裸鼠、荷MC38-hPD-L1肿瘤人源化转基因小鼠及食蟹猴中开展剂量递增生物分布与PET/CT显像,并将猴PET图像用OLINDA2.1外推估算成人男女辐射剂量。结果显示该探针在生理介质和人血清中稳定,肿瘤摄取快速且特异,较低剂量下肿瘤/本底比更佳,注射185 MBq时估算有效剂量致患者辐射剂量为4.1 mSv。

要点

  • 68Ga-NOTA-Nb109在生理介质及人血清中稳定,在hPD-L1肿瘤中呈快速且特异性摄取。
  • 人源化小鼠估算ED50约5.4 µg,给药质量显著影响整体生物分布,较低剂量获更佳肿瘤/本底比。
  • 食蟹猴采用单次15 μg/kg剂量行PET/CT显像,脾/肌肉比在给药后即刻至4小时超过10。

核心结论

  • 68Ga-NOTA-Nb109在离体生物分布研究和猴PET/CT显像中均显示在hPD-L1移植瘤中特异性蓄积。
  • 剂量递增分布数据为后续应用提供了推荐剂量范围,剂量学研究确认了该探针的安全性。

研究设计与样本

  • 采用68Ga经NOTA螯合剂标记Nb109制备68Ga-NOTA-Nb109。
  • 在荷A375-hPD-L1肿瘤BALB/c裸鼠和荷MC38-hPD-L1肿瘤C57-hPD-L1转基因小鼠中单次静脉给药行剂量递增生物分布研究。
  • 在食蟹猴中确认剂量,并将猴PET图像生物分布数据用OLINDA2.1软件外推估算成年男性和女性的辐射剂量。

主要发现

  • 68Ga-NOTA-Nb109在生理介质和人血清中稳定,离体生物分布显示在A375-hPD-L1或MC38-hPD-L1肿瘤中快速且特异性摄取。
  • 人源化小鼠中估算ED50约为5.4 µg。
  • 注射质量(裸鼠0.3–100 µg、人源化小鼠约1–100 µg)显著影响整体生物分布,较低剂量(裸鼠0.3–10 µg、人源化小鼠约1 µg)获得更佳肿瘤/本底比,提示给药质量低于估算ED50时肿瘤摄取最大。
  • 食蟹猴采用单次15 μg/kg剂量行PET/CT显像,除肾和尿膀胱(与代谢和排泄相关)外,脾中检测到最高特异性且持续摄取,给药后即刻至4小时脾/肌肉比超过10。
  • 注射185 MBq 68Ga-NOTA-Nb109后估算患者辐射剂量为4.1 mSv。

关键数值与推荐

  • 食蟹猴PET/CT显像采用单次15 μg/kg剂量。
  • 人源化小鼠估算ED50约为5.4 µg。
  • 注射185 MBq 68Ga-NOTA-Nb109时估算有效剂量对应患者辐射剂量为4.1 mSv。
  • 脾/肌肉比在给药后即刻至4小时超过10。

临床怎么用

  • 原文结论指出剂量递增分布数据为68Ga-NOTA-Nb109的进一步使用提供了推荐剂量范围。
  • 原文结论指出剂量学研究确认了该探针的安全性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunotherapy is a valuable option for cancer treatment, and the curative effect of anti-PD-1/PD-L1 therapy correlates closely with PD-L1 expression levels. Positron emission tomography (PET) imaging of PD-L1 expression is feasible using 68Ga-NOTA-Nb109 nanobody. 68Ga-NOTA-Nb109 was generated by radionuclide (68Ga) labeling of Nb109 using a NOTA chelator. To facilitate clinical trials, we explored the optimal dose range of 68Ga-NOTA-Nb109 in BALB/c A375-hPD-L1 tumor-burdened nude mice and C57-hPD-L1 transgenic MC38-hPD-L1 tumor-burdened mice by administration of a single intravenous dose of 68Ga-NOTA-Nb109 and confirmed the dose in cynomolgus monkeys. The biodistribution data of cynomolgus monkey PET images were extrapolated to estimate the radiation dose for the adult male and female using OLINDA2.1 software. RESULTS: 68Ga-NOTA-Nb109 was stable in physiologic media and human serum. Ex vivo biodistribution studies showed rapid and specific uptake in A375-hPD-L1 or MC38-hPD-L1 tumors. The estimated ED50 was approximately 5.4 µg in humanized mice. The injected mass (0.3-100 µg in nude mice and approximately 1-100 µg in humanized mice) greatly influenced the general biodistribution, with a better tumor-to-background ratio acquired at lower doses of Nb109 (0.3-10 µg in nude mice and approximately 1 µg in humanized mice), indicating maximum uptake in tumors at administered mass doses below the estimated ED50. Therefore, a single 15-μg/kg dose was adopted for the PET/CT imaging in the cynomolgus monkey. The highest specific and persistent uptake of the tracer was detected in the spleen, except the levels in the kidney and urine bladder, which was related to metabolism and excretion. The spleen-to-muscle ratio of the tracer exceeded 10 from immediately to 4 h after administration, indicating that the dose was appropriate. The estimated effective dose was calculated to yield a radiation dose of 4.1 mSv to a patient after injecting 185 MBq of 68Ga-NOTA-Nb109. CONCLUSION: 68Ga-NOTA-Nb109 showed specific accumulation in hPD-L1 xenografts in ex vivo biodistribution studies and monkey PET/CT imaging. The dose escalation distribution data provided a recommended dose range for further use, and the safety of the tracer was confirmed in dosimetry studies.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Yang Y, Wang C, Wang Y, et al. Dose escalation biodistribution, positron emission tomography/computed tomography imaging and dosimetry of a highly specific radionuclide-labeled non-blocking nanobody. EJNMMI Res. 2021. PMID: 34718889. doi:10.1186/s13550-021-00854-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。